Abemaciclib metabolite M20

• CAT Number: I017816
• CAS Number: 2138499-06-4
• Molecular Formula: C₂₇H₃₂F₂N₈O
• Molecular Weight: 522.59
• Purity: ≥95%
• Storage: Store at -20°C
• IUPAC Name: [6-[2-[[5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl]amino]-5-fluoropyrimidin-4-yl]-4-fluoro-1-propan-2-ylbenzimidazol-2-yl]methanol
• InChI: InChI=1S/C27H32F2N8O/c1-4-35-7-9-36(10-8-35)15-18-5-6-23(30-13-18)32-27-31-14-21(29)25(34-27)19-11-20(28)26-22(12-19)37(17(2)3)24(16-38)33-26/h5-6,11-14,17,38H,4,7-10,15-16H2,1-3H3,(H,30,31,32,34)
• InChIKey: KUJBDJBMXOTNIT-UHFFFAOYSA-N
• SMILES: CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)CO)F

Abemaciclib Metabolite M20（Cat No.:I017816）is a primary metabolite of abemaciclib, a potent CDK4/6 inhibitor used in cancer treatment. M20 retains activity against cyclin-dependent kinases, playing a role in cell cycle regulation by inhibiting the transition from the G1 to the S phase. This metabolite is crucial in understanding the pharmacokinetics, efficacy, and safety profile of abemaciclib in cancer therapy, particularly in breast cancer. Studying M20 helps researchers evaluate the drug’s metabolism, bioavailability, and therapeutic impact, providing insights for optimizing treatment strategies and drug development.

Reference

[1]. Richard Paul Beckmann, et al. Combination therapy with notch and cdk4/6 inhibitors for the treatment of cancer. WO2017180389A1.